Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIncreasing your Mounjaro dose strengthens the medicine's effect on two gut-hormone receptors, GIP and GLP-1, which together suppress appetite more powerfully, slow digestion further and can deepen weight loss over time. That said, each step up also carries a higher risk of side effects, which is why tirzepatide's titration schedule is structured around tolerability, not speed. Mounjaro is a prescription-only medicine; a qualified prescriber decides whether and when a dose increase is right for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You've been on your current pen for a month. The nausea faded weeks ago. Your appetite is under better control than it was, but weight loss has slowed and you're reading the packaging wondering what moving to the next strength would actually change. That hesitation is completely understandable, it's a real medicine, a real decision, and the answer isn't simply 'more is better'.
At a biological level, each higher strength delivers a larger dose of tirzepatide per weekly injection, which amplifies how strongly it binds to GIP and GLP-1 receptors in the gut, pancreas and brain. The practical result is a stronger brake on appetite, a longer delay in stomach emptying and, for many people, a shift in the rate of weight loss. If you'd like the full picture, our page on what Mounjaro does to the body goes into this mechanism in more detail.
Clinical trial data give a sense of the scale involved. In SURMOUNT-1, participants who reached 15 mg lost an average of around 20–21% of body weight over 72 weeks, compared with smaller reductions at lower maintenance doses. The SURMOUNT-1 trial, published in the New England Journal of Medicine, involved 2,539 adults, the numbers are large enough to draw meaningful conclusions about dose-response.
The first pen (2.5 mg) exists almost entirely to let your system adjust. Its job is reducing early side effects, not driving significant weight loss. Moving to 5 mg is where most people notice Mounjaro working in a more tangible way: appetite drops more noticeably and food feels less urgent.
From 5 mg upward, each step tends to produce incremental improvements in weight loss for people who tolerate the previous dose well. A minority of people find 5 mg or 7.5 mg is the highest dose their body handles comfortably; there's no clinical failure in stopping there. The maximum licensed dose is 15 mg, reached after titrating through 2.5, 5, 7.5, 10 and 12.5 mg in sequence, whether you have to keep increasing Mounjaro is a common question worth reading through separately.
Each dose increase can temporarily bring back side effects that had settled: nausea, loose stools, slower digestion or reflux are the most commonly reported. The NHS tirzepatide medicines page sets out the full side-effect profile. These reactions typically peak in the first few days after the injection at a new dose and ease as the body acclimates, usually within one to two weeks. Staying well-hydrated and eating smaller portions helps most people through the adjustment.
A higher dose is not always the next step. If side effects are still significant at your current strength, or if certain health markers need reviewing, your prescriber may recommend staying where you are for longer, or not going further. This is why clinical oversight before each change matters.
There are also situations where a dose increase is paused because of medicines absorption. Women taking oral contraceptives should use an additional non-oral method for the first four weeks of any new Mounjaro dose, because the slowing of gastric emptying can affect how the pill is absorbed. NHS England's weight-management injections guidance covers this, and the same principle applies to some other oral medicines, worth discussing openly with your prescriber.
If you have questions about whether you're on the right dose, or whether the time is right to step up, guidance on managing your treatment day to day covers practical steps, and our FAQs address the questions people most commonly bring to our team.
At nume, no dose increase goes through on autopilot. Every repeat order is reviewed by a GPhC-registered prescriber, a real clinician reading your update, not software making a default decision. If you're unsure whether to request a step up, that review is the right place to have the conversation. Tolerability, progress and any other medicines you're taking all factor in.
For context on what the full private treatment pathway looks like, including how pricing is structured, the weight-loss treatment options page sets it out plainly. If you'd like to understand the broader clinical evidence behind tirzepatide before your next review, our Mounjaro overview brings it together in one place, including a look at what the name Mounjaro actually means and where it comes from.
When you're ready to speak to someone, our prescribers are available seven days a week and can review your situation the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.